Company News: Pfizer

Share this article:

A study conducted by researchers at the University of Washington and published in medical journal The Lancet has found that a popular injectable contraceptive in Africa doubles the risk of women becoming infected with H.I.V. Nearly 4,000 couples who use the injectable were studied, hailing from countries scattered around Africa—Zambia, South Africa and Uganda, to name a few—and it was found that for women who are already H.I.V.-positive, their male partners were twice as likely to become infected than if their partner used no contraception at all. The branded version of the drug is Depo-Provera, manufactured by Pfizer, and reps for the pharma have yet to comment on the study.

Share this article:

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.